The UK and US have hammered out a significant trade agreement that will ensure zero levies on UK medicine shipments being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the public health system. This move ensures that tariffs on these key exports will stay at zero for a period of the next three years.
This agreement follows earlier warnings to hike duties on branded drug imports, with figures floated reaching 100%.
"This agreement with the UK bolsters the global environment for new treatments and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," a release noted.
Commercial Importance
Pharmaceuticals are one of the Britain's most significant goods shipped to the United States, which is clearly the largest market for large British pharmaceutical firms.
Export figures reveal that in the year prior to the third quarter, the UK exported medicines valued at billions to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This agreement protects jobs, stimulates investment and facilitates the UK to become a international leader for life sciences," a government official stated.
Detailed British Pledges
The agreement involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. Last year, rebates exceeded twenty percent.
Recent Tensions
This agreement follows a protracted tension between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
This friction were heightened by assertions that American patients were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or cancelled, while major investments have been directed toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its total funding over the past decade.
